Doctor Michal Laufer-Perl

Doctor Michal Laufer-Perl

Tel Aviv Sourasky Medical Center, Tel Aviv (Israel)

Member of:

My name Is Michal Laufer Perl (MD, MHA) and I'm the director of the cardio-vascular clinics and practicing in Heart Failure and Cardio-oncology in Tel Aviv Sourasky Medical Center in Israel. I've established the cardio-oncology clinic in our facility in 2016 which today is the largest clinic in Israel with 1300 visits per year. As part of the cardio-oncology clinic we established a prospective registry (ICOR) evaluating all the patients referred to the cardio-oncology clinics and counting for over 600 patients with a number of studies already published and presented in international conferences.

Presentations

The predictive value of routine troponin measurements in patients treated with immune checkpoint inhibitors

Event: Heart Failure 2024

Topic: Cardio-Oncology

Session: How to improve prognosis in cardio-oncology

Access

Atrial mechanics in heart failure with preserved ejection fraction: effect of a no-implant interatrial shunt

Event: Heart Failure 2024

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Session: Chronic heart failure - pathophysiology and mechanisms 10

Access

Association between beta-1-blockers and reduced efficacy of pembrolizumab in non-small cell lung cancer

Event: Heart Failure 2023

Topic: Cardio-Oncology

Session: ePosters in cardiovascular disease in special populations 2

Access

The prognostic value of sodium-glucose co-transporter-2 inhibitors therapy among patients with cancer and diabetes mellitus, treated with immune checkpoint inhibitors

Event: Heart Failure 2023

Topic: Cardio-Oncology

Session: ePosters in cardiovascular disease in special populations 1

Access

Multi-centre clinical outcomes of a no-implant interatrial shunt for heart failure with preserved and reduced ejection fraction: update from the ALLEVIATE-HF program

Event: Heart Failure 2023

Topic: Multidisciplinary Interventions

Session: Chronic heart failure - diagnostic methods

Access

COVID-19 vaccine-induced myocarditis vs. Immune checkpoint inhibitor-induced myocarditis - Same but different?

Event: ESC Congress 2022

Topic: Cardio-Oncology

Session: COVID-19 and cardiovascular disease in special populations

Access

Valvular changes following anthracycline therapy: is it time to look beyond ejection fraction?

Event: ESC Congress 2022

Topic: Cardio-Oncology

Session: Cardio-oncology 1

Access

High neutrophil-to-lymphocyte ratio as an early sign for cardiotoxicity in breast cancer patients treated with anthracycline

Event: Heart Failure 2022

Topic: Cardio-Oncology

Session: Heart Failure ePosters - focus on Comorbidities and special population

Access

Right ventricle strain changes in patients with breast cancer during anthracycline therapy

Event: ESC Congress 2021 - The Digital Experience

Topic: Cardio-Oncology

Session: Cardiovascular Disease in Special Populations ePosters

Access

Repetitive milrinone therapy in ambulatory advanced heart failure patients

Event: Heart Failure 2021

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Session: ePoster session

Access

ESC 365 is supported by

Explore sponsored resources

Doctor Michal Laufer-Perl

Biography

Contributor content

The predictive value of routine troponin measurements in patients treated with immune checkpoint inhibitors

Atrial mechanics in heart failure with preserved ejection fraction: effect of a no-implant interatrial shunt

Association between beta-1-blockers and reduced efficacy of pembrolizumab in non-small cell lung cancer

The prognostic value of sodium-glucose co-transporter-2 inhibitors therapy among patients with cancer and diabetes mellitus, treated with immune checkpoint inhibitors

Multi-centre clinical outcomes of a no-implant interatrial shunt for heart failure with preserved and reduced ejection fraction: update from the ALLEVIATE-HF program

COVID-19 vaccine-induced myocarditis vs. Immune checkpoint inhibitor-induced myocarditis - Same but different?

Valvular changes following anthracycline therapy: is it time to look beyond ejection fraction?

High neutrophil-to-lymphocyte ratio as an early sign for cardiotoxicity in breast cancer patients treated with anthracycline

Right ventricle strain changes in patients with breast cancer during anthracycline therapy

Repetitive milrinone therapy in ambulatory advanced heart failure patients

ESC 365 is supported by

Doctor Michal Laufer-Perl Follow

Biography

Contributor content

The predictive value of routine troponin measurements in patients treated with immune checkpoint inhibitors

Atrial mechanics in heart failure with preserved ejection fraction: effect of a no-implant interatrial shunt

Association between beta-1-blockers and reduced efficacy of pembrolizumab in non-small cell lung cancer

The prognostic value of sodium-glucose co-transporter-2 inhibitors therapy among patients with cancer and diabetes mellitus, treated with immune checkpoint inhibitors

Multi-centre clinical outcomes of a no-implant interatrial shunt for heart failure with preserved and reduced ejection fraction: update from the ALLEVIATE-HF program

COVID-19 vaccine-induced myocarditis vs. Immune checkpoint inhibitor-induced myocarditis - Same but different?

Valvular changes following anthracycline therapy: is it time to look beyond ejection fraction?

High neutrophil-to-lymphocyte ratio as an early sign for cardiotoxicity in breast cancer patients treated with anthracycline

Right ventricle strain changes in patients with breast cancer during anthracycline therapy

Repetitive milrinone therapy in ambulatory advanced heart failure patients

ESC 365 is supported by

Doctor Michal Laufer-Perl